Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Cancer Research UK
Hoffmann-La Roche
Karolinska University Hospital
Eli Lilly and Company
Tanabe Pharma America, Inc.
Cancer Research UK
Eli Lilly and Company
Day One Biopharmaceuticals, Inc.
Vyriad, Inc.
Société Algérienne de Formation et de Recherche en Oncologie
Travera Inc
JS InnoPharm, LLC
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
EpicentRx, Inc.
Eli Lilly and Company
Purple Biotech Ltd.
Aminex Therapeutics, Inc.
Travera Inc
Mayo Clinic
Fudan University
Boston Pharmaceuticals
National Cancer Institute (NCI)
Institut Bergonié
Xencor, Inc.
M.D. Anderson Cancer Center
Novartis
Infinity Pharmaceuticals, Inc.
Amgen
Fore Biotherapeutics
Eli Lilly and Company
SWOG Cancer Research Network
University of Southern California
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Exelixis
Rutgers, The State University of New Jersey
The University of Texas Health Science Center, Houston
Adherex Technologies, Inc.